34
Participants
Start Date
January 19, 2022
Primary Completion Date
March 9, 2024
Study Completion Date
April 9, 2024
ZL-1211
Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
Zai Lab Site 2025, New York
Zai Lab Site 2023, Fairfax
Zai Lab Site 2011, Nashville
Zai Lab Site 2015, Cincinnati
Zai Lab Site 2014, Indianapolis
Zai Lab Site 2012, Scottsdale
Zai Lab Site 2016, Lynwood
Zai Lab Site 2022, Tacoma
Zai Lab Site 2013, Spokane
Zai Lab Site 1548, Beijing
Zai Lab Site 1551, Harbin
Zai Lab Site 1542, Shanghai
Zai Lab Site 1725, Hefei
Zai Lab Site 1539, Jinan
Zai Lab Site 1529, Hangzhou
Zai Lab Site 1714, Hangzhou
Zai Lab Site 1537, Wuhan
Zai Lab Site 1549, Zhengzhou
Zai Lab Site 1202, Zhengzhou
Zai Lab Site 1712, Chengdu
Zai Site 2020, Hackensack
Zai Biopharmaceutical (Suzhou) Co., Ltd.
INDUSTRY